Hans Hammers, MD, PhD

Hans Hammers, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center

Articles by Hans Hammers, MD, PhD

Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
View More
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel talks about nonclear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel shared their approach to treatment selection for clear cell kidney cancer.
Hans Hammers, MD, PhDRenal Cell Carcinoma | September 8, 2023
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.